Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gantenerumab in Prodromal Alzheimer's Disease (Scarlet Road)
NCT01224106Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2010
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of gantenerumab in Alzheimer's disease (AD) (5 arms), sponsored by Roche. Primary endpoints: Clinical Dementia Rating Sum of Boxes at 104 weeks and Adverse Events and Serious Adverse Events at 5 years. Started Nov 2010; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01224106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01224106.